secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-277030
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies Q3 net loss $17.3M; cash $213M; VITESSE Phase 3 delayed by clinical hold
--------------------------------------------------------------------------------

- Q3 net loss of $17.3M ($0.18 per share); nine-month net loss $57.0M ($0.79 per share).
- Cash and cash equivalents $212.7M as of Sept 30, 2022, up from $77.3M at Dec 31, 2021.
- Operating expenses decreased 22% in Q3 and 26% in first nine months vs prior year.
- Partial clinical hold on VITESSE Phase 3 study; first patient screen not expected by year-end 2022.
- Cash used in operating activities fell 35% YoY; cost containment measures cited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312522277030/0001193125-22-277030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312522277030/d411212d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-277030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer